Current chemotherapy of small cell lung cancer

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Since the advent of effective combinations in the early 1970s, results from chemotherapy for small cell lung cancer have improved very little. Maintenance chemotherapy appears of no benefit. Although attractive theoretically, 'non-cross-resistant' combinations may not yet exist, and most data do not support alternating 1 regimen with another. Anticoagulant therapy with warfarin probably does not have a meaningful impact on survival, at least in extensive stage disease. To date the addition of VP-16, an active new agent, has not produced improvement in survival over earlier programs. The most promising leads to date involve dose escalation, especially with cyclophosphamide. Moderate 'outpatient' escalation in limited disease induction therapy produced survival benefit in a randomized trial, and several studies indicate that the incidence of complete response can be increased by more intensive, inpatient 'consolidation' with cyclophosphamide with or without other drugs after the induction period. Some form of local therapy, however, will be necessary to control disease in the chest, even with maximal dose intensification.

Original languageEnglish (US)
JournalChest
Volume89
Issue number4 SUPPL.
StatePublished - 1986
Externally publishedYes

Fingerprint

Small Cell Lung Carcinoma
Drug Therapy
Cyclophosphamide
Maintenance Chemotherapy
Etoposide
Warfarin
Anticoagulants
Inpatients
Cohort Studies
Outpatients
Thorax
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Current chemotherapy of small cell lung cancer. / Livingston, Robert B.

In: Chest, Vol. 89, No. 4 SUPPL., 1986.

Research output: Contribution to journalArticle

@article{37a810e3e7be4a8daa544d8a6a9bd5cb,
title = "Current chemotherapy of small cell lung cancer",
abstract = "Since the advent of effective combinations in the early 1970s, results from chemotherapy for small cell lung cancer have improved very little. Maintenance chemotherapy appears of no benefit. Although attractive theoretically, 'non-cross-resistant' combinations may not yet exist, and most data do not support alternating 1 regimen with another. Anticoagulant therapy with warfarin probably does not have a meaningful impact on survival, at least in extensive stage disease. To date the addition of VP-16, an active new agent, has not produced improvement in survival over earlier programs. The most promising leads to date involve dose escalation, especially with cyclophosphamide. Moderate 'outpatient' escalation in limited disease induction therapy produced survival benefit in a randomized trial, and several studies indicate that the incidence of complete response can be increased by more intensive, inpatient 'consolidation' with cyclophosphamide with or without other drugs after the induction period. Some form of local therapy, however, will be necessary to control disease in the chest, even with maximal dose intensification.",
author = "Livingston, {Robert B}",
year = "1986",
language = "English (US)",
volume = "89",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "4 SUPPL.",

}

TY - JOUR

T1 - Current chemotherapy of small cell lung cancer

AU - Livingston, Robert B

PY - 1986

Y1 - 1986

N2 - Since the advent of effective combinations in the early 1970s, results from chemotherapy for small cell lung cancer have improved very little. Maintenance chemotherapy appears of no benefit. Although attractive theoretically, 'non-cross-resistant' combinations may not yet exist, and most data do not support alternating 1 regimen with another. Anticoagulant therapy with warfarin probably does not have a meaningful impact on survival, at least in extensive stage disease. To date the addition of VP-16, an active new agent, has not produced improvement in survival over earlier programs. The most promising leads to date involve dose escalation, especially with cyclophosphamide. Moderate 'outpatient' escalation in limited disease induction therapy produced survival benefit in a randomized trial, and several studies indicate that the incidence of complete response can be increased by more intensive, inpatient 'consolidation' with cyclophosphamide with or without other drugs after the induction period. Some form of local therapy, however, will be necessary to control disease in the chest, even with maximal dose intensification.

AB - Since the advent of effective combinations in the early 1970s, results from chemotherapy for small cell lung cancer have improved very little. Maintenance chemotherapy appears of no benefit. Although attractive theoretically, 'non-cross-resistant' combinations may not yet exist, and most data do not support alternating 1 regimen with another. Anticoagulant therapy with warfarin probably does not have a meaningful impact on survival, at least in extensive stage disease. To date the addition of VP-16, an active new agent, has not produced improvement in survival over earlier programs. The most promising leads to date involve dose escalation, especially with cyclophosphamide. Moderate 'outpatient' escalation in limited disease induction therapy produced survival benefit in a randomized trial, and several studies indicate that the incidence of complete response can be increased by more intensive, inpatient 'consolidation' with cyclophosphamide with or without other drugs after the induction period. Some form of local therapy, however, will be necessary to control disease in the chest, even with maximal dose intensification.

UR - http://www.scopus.com/inward/record.url?scp=0022655695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022655695&partnerID=8YFLogxK

M3 - Article

C2 - 3007042

AN - SCOPUS:0022655695

VL - 89

JO - Chest

JF - Chest

SN - 0012-3692

IS - 4 SUPPL.

ER -